BioMarin Pharmaceutical (BMRN) Stock
$56.01
−0.20% Close Nov 6
Open interactive chartBMRN stock price and performance
BMRN stock closed at $56.01 on Nov 6, 2026. The tables below use that final daily session.
- Last close
- $56.01
- Day range
- $55.00 to $56.08
- 52-week range
- $49.26 to $70.98
- From 52-week high
- −21.1%
- Average volume (50 days)
- 2.3M
- 1 week
- −4.3%
- 1 month
- +2.0%
- 3 months
- −18.7%
- Year to date
- −5.8%
- 1 year
- +6.1%
- 3 years
- −33.3%
- 5 years
- −29.3%
Is BMRN stock in an uptrend?
No, BMRN stock is in a downtrend: it does not meet the Minervini Trend Template criteria and neither Daily Pivot Breakout momentum filter is active. Price is below its 200-day moving average.
- Daily Pivot momentum filters
- 0 of 2 active
- 100-day ROC
- +1.6% filter at 40%: off
- 100-day EMA slope
- +6.6% filter at 25%: off
- Trend state
- Downtrend
- Minervini Trend Template
- Not met on the latest scan
- 50-day average
- Below
- 150-day average
- Below
- 200-day average
- Below
- 200-day slope (1 month)
- −0.44%
- ATR (14) % of price
- 3.50%
Momentum filters from the Daily Pivot Breakout indicator: 100-day rate of change and 100-day EMA slope, each against its minimum.
Is BMRN stock in a Stage 2 uptrend?
No. BMRN stock is in Stage 3 (topping) by our Weinstein stage analysis: its 30-week moving average has flattened after an advance.
- Weinstein stage
- Stage 3 (topping)
- 30-week SMA
- $58.62
- 30-week slope (4 weeks)
- +0.39%
- Mansfield RS vs SPY
- -5.75
Weinstein stage analysis uses weekly closes against the 30-week moving average and Mansfield relative strength versus SPY. See the free Stage 2 stocks screener.
BMRN support and resistance levels
| Level | Price | From close |
|---|---|---|
| 50-day SMA | $59.69 | +6.6% |
| 30-week SMA | $58.62 | +4.7% |
| 150-day SMA | $58.48 | +4.4% |
| 200-day SMA | $58.45 | +4.4% |
| Daily Pivot resistance (pivot high) | $57.59 | +2.8% |
| 21-day EMA | $56.78 | +1.4% |
| 9-day EMA | $56.45 | +0.8% |
| Latest Daily Pivot low | $53.90 | −3.8% |
Levels above the close act as resistance, levels below as support. Last close $56.01.
BMRN breakout and scanner signals
| Scanner | Last signal (free view, 5 sessions late) | Past year |
|---|---|---|
| VCP | None in the last year | 0 |
| RSI Divergence | Nov 5, 2025 | 0 |
| Weinstein Stage Analysis | Sep 18, 2026 | 29 |
| Daily Pivot Breakout | None in the last year | 0 |
| Minervini Trend Template | Sep 16, 2026 | 1 |
| Episodic Pivot | None in the last year | 0 |
| Ichimoku TK cross | Sep 14, 2026 (bearish) | 10 |
| 9/21 EMA cross | Sep 17, 2026 (bearish) | 10 |
| Golden / Death Cross | Jul 22, 2026 | 3 |
| RS Rating | None in the last year | 0 |
BMRN seasonality by month
- Jan+3.9%62% up
- Feb+1.6%48% up
- Mar+0.2%44% up
- Apr−2.1%48% up
- May+0.8%52% up
- Jun+1.7%59% up
- Jul+4.0%67% up
- Aug−0.6%56% up
- Sep−2.0%41% up
- Oct−2.3%41% up
- Nov+6.8%85% up
- Dec+4.1%65% up
Average monthly return over 26+ years of stored daily closes, and the share of years each month closed higher.
BMRN earnings history
| Reported | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Nov 2, 2026 | $-0.11 | $0.23 | +309.1% |
| Oct 13, 2026 | $13.09 | $17.01 | +30.0% |
| Aug 6, 2026 | $0.95 | $1.20 | +26.3% |
| Jul 23, 2026 | $3.32 | $3.52 | +6.0% |
| Jul 9, 2026 | $0.04 | $-0.02 | −150.0% |
BMRN bull and bear case
What looks strong
- The 50, 150 and 200-day averages are stacked in uptrend order.
What looks weak
- Neither Daily Pivot momentum filter is active (100-day ROC 1.6%, 100-day EMA slope 6.6%; the filters need 40% and 25%).
- Does not meet the Minervini Trend Template on the latest scan.
- Price is below the 200-day moving average, which is falling.
- Net income over the last 12 months is negative.
Drawn only from the data on this page. Not a recommendation.
BMRN news and SEC filings, last 30 days
Source: SEC EDGAR.
BMRN insider trading and risks
- Buys, last 90 days
- 0 ($0)
- Sales, last 90 days
- 0 ($0)
- Buys, last 12 months
- 0 ($0)
- Sales, last 12 months
- 0 ($0)
Risk flags from the data
- Net income over the last 12 months is negative.
Insider trades: SEC Form 4 open-market purchases and sales.
BMRN valuation and fundamentals
- Market cap
- $10.85B
- Enterprise value
- $14.31B
- P/E (trailing)
- 151.6
- P/E (forward)
- 8.8
- PEG
- -1.86
- Price to sales
- 2.97
- Price to book
- 1.73
- EV to EBITDA
- 16.7
- Gross margin
- +79.5%
- Operating margin
- +26.6%
- Profit margin
- −0.5%
- Return on equity
- −0.3%
- Revenue (TTM)
- $3.66B
- Revenue growth (quarter, y/y)
- +32.0%
- Cash
- $736.0M
- Debt
- $4.19B
- Beta
- 0.23
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $3.22B | $348.9M | $828.0M |
| 2024 | $2.85B | $426.9M | $502.6M |
| 2023 | $2.42B | $167.6M | $4.7M |
| 2022 | $2.10B | $141.6M | $174.2M |
BMRN dividends and splits
- Dividend yield
- 0.00%
- Payout ratio
- 0.0%
Who owns BMRN?
- Shares outstanding
- 193.5M
- Float
- 192.8M
- Held by insiders
- +0.3%
- Held by institutions
- +103.1%
- Short interest (% of shares)
- +6.2%
- Days to cover
- 5.3
What does BioMarin Pharmaceutical Inc. do?
- CEO
- Mr. Alexander Hardy
- Employees
- 3,221
- Headquarters
- San Rafael, CA, United States
- Website
- biomarin.com
